[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.241.171. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
April 1974

Differentiated Thyroid CarcinomasTreatment of Distant Metastases

Author Affiliations

Ann Arbor, Mich
From the Section of General Surgery (Drs. Harness and Thompson) and Division of Nuclear Medicine (Drs. Sisson and Beierwaltes), University of Michigan Medical Center, Ann Arbor, Mich.

Arch Surg. 1974;108(4):410-419. doi:10.1001/archsurg.1974.01350280016004
Abstract

During the 26-year period from 1947 to 1973, 333 patients with differentiated thyroid carcinomas were treated with sodium iodide I 131 post-operatively. Thirty-six of these (10.6%) had metastases to lung or bone or both. The mean age at the time of diagnosis was 36.1 years (range, 6 to 69 years). Mortality from thyroid carcinomas was 27.8%. Average follow-up interval from diagnosis was 19.8 years for those with papillary carcinomas and lung metastases and 23.0 years for those with follicular carcinomas and lung metastases. Although seven of ten patients with bone metastases died, the five-year survival was 100% in this group. The average dose of sodium iodide I 131 was 383.2 millicuries for papillary distant metastases and 571.2 millicuries for follicular metastases. Total thyroidectomy prior to treatment of distant metastases with sodium iodide I 131 is important for successful management.

×